A clinical study into weight loss drugs for pets just launched, with results from the trial expected by next summer.

The FINANCIAL — Merck on June 13 announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on biologic insulin glargine candidate for the treatment of people with ...

The FINANCIAL — Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR (insulin glargine), Eli Lilly and Company and Boehringer Ingelheim’s biosimilar insulin glargine, ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...